BRPI0510743A - processo para a preparação de entecavir e intermediários dos mesmos mediante oxidação de carbono-silìcio e composição quìmica - Google Patents

processo para a preparação de entecavir e intermediários dos mesmos mediante oxidação de carbono-silìcio e composição quìmica

Info

Publication number
BRPI0510743A
BRPI0510743A BRPI0510743-1A BRPI0510743A BRPI0510743A BR PI0510743 A BRPI0510743 A BR PI0510743A BR PI0510743 A BRPI0510743 A BR PI0510743A BR PI0510743 A BRPI0510743 A BR PI0510743A
Authority
BR
Brazil
Prior art keywords
carbon
preparation
entecavir
chemical composition
intermediates
Prior art date
Application number
BRPI0510743-1A
Other languages
English (en)
Inventor
Maotang X Zhou
Purushotham Vemishetti
Yadagiri R Pendri
Ambarish K Singh
Siva J Prasad
Ulhas P Dhokte
Xinhua Qian
Pia Mountford
Kerry B Hartung
Helen Sailes
Emily A Reff
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0510743A publication Critical patent/BRPI0510743A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/16—Preparation of ethers by reaction of esters of mineral or organic acids with hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/26—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0838—Compounds with one or more Si-O-Si sequences
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Silicon Compounds (AREA)

Abstract

PROCESSO PARA A PREPARAçãO DE ENTECAVIR E INTERMEDIáRIOS DOS MESMOS MEDIANTE OXIDAçãO DE CARBONO-SILìCIO E COMPOSIçãO QUìMICA. A presente invenção refere-se a processos para a preparação de entecavir (1) e seus novos intermediários mediante uso de oxidação de carbono-silício.
BRPI0510743-1A 2004-06-04 2005-06-03 processo para a preparação de entecavir e intermediários dos mesmos mediante oxidação de carbono-silìcio e composição quìmica BRPI0510743A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57689904P 2004-06-04 2004-06-04
US11/143,268 US7511139B2 (en) 2004-06-04 2005-06-02 Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
PCT/US2005/019633 WO2005118585A1 (en) 2004-06-04 2005-06-03 Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation

Publications (1)

Publication Number Publication Date
BRPI0510743A true BRPI0510743A (pt) 2007-11-20

Family

ID=35449926

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510743-1A BRPI0510743A (pt) 2004-06-04 2005-06-03 processo para a preparação de entecavir e intermediários dos mesmos mediante oxidação de carbono-silìcio e composição quìmica

Country Status (12)

Country Link
US (3) US7511139B2 (pt)
EP (1) EP1751158A4 (pt)
JP (1) JP5236288B2 (pt)
KR (1) KR20070029737A (pt)
AU (1) AU2005251377A1 (pt)
BR (1) BRPI0510743A (pt)
CA (1) CA2569484A1 (pt)
IL (1) IL179753A0 (pt)
MX (1) MXPA06014003A (pt)
NO (1) NO20066078L (pt)
RU (1) RU2384582C2 (pt)
WO (1) WO2005118585A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101899063B (zh) * 2002-12-11 2012-12-12 布里斯托尔-迈尔斯斯奎布公司 制备抗病毒药[1S-(1α,3α,4β)]-2-氨基-1,9-二氢-9-[4-羟基-3-(羟甲基)-2-亚甲环戊基]-6H-嘌呤-6-酮的方法
US20070060599A1 (en) * 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
CN101210015B (zh) * 2006-12-26 2010-09-22 上海国创医药有限公司 一种乙肝治疗药物恩替卡韦的制备方法
CN101245068A (zh) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
CN101284799B (zh) 2007-03-23 2013-04-03 浙江医药股份有限公司新昌制药厂 咖啡酰奎宁酸含氮衍生物及其制备方法和其药物组合物及用途
CN101397333A (zh) 2007-09-27 2009-04-01 浙江医药股份有限公司新昌制药厂 去羟基万古霉素及其制备方法、和其药物组合物及其用途
KR101150254B1 (ko) 2008-12-26 2012-06-12 한미사이언스 주식회사 신규 중간체 및 이를 활용한 엔테카비르 제조방법
CN101828693B (zh) 2009-03-09 2013-01-02 浙江医药股份有限公司新昌制药厂 制备低粘度高流动性类胡萝卜素油悬浮液的方法及其应用
CA2777018C (en) * 2009-10-12 2014-04-29 Hanmi Holdings Co., Ltd. Novel method for preparing entecavir and intermediate used therein
CN101781301B (zh) * 2010-01-15 2013-04-10 复旦大学 一种制备恩替卡韦的方法
US8481728B2 (en) * 2010-02-16 2013-07-09 Scinopharm Taiwan, Ltd. Process for preparing entecavir and its intermediates
CN102417506B (zh) * 2010-09-27 2016-04-06 杭州赛利药物研究所有限公司 一种抗病毒药物恩替卡韦的制备方法
US20140194383A1 (en) 2011-04-07 2014-07-10 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
WO2013058825A1 (en) * 2011-04-07 2013-04-25 Cornell University Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same
KR101462850B1 (ko) * 2012-05-31 2014-12-04 일동제약주식회사 고순도 엔테카비르 일수화물의 제조방법
CN104177394B (zh) * 2013-05-23 2017-12-05 浙江星月药物科技股份有限公司 恩替卡韦中间体及其制备方法
CN104177396A (zh) * 2013-05-23 2014-12-03 浙江星月药物科技股份有限公司 恩替卡韦中间体及其制备方法
CN107513065B (zh) * 2017-08-03 2021-06-22 浙江华纳药业有限公司 一种恩替卡韦中间体iv制备方法
CN109232637B (zh) * 2018-10-29 2020-11-24 常州博海威医药科技股份有限公司 一种恩替卡韦中间体的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4471130A (en) * 1980-08-06 1984-09-11 The Board Of Trustees Of The Leland Stanford Junior University Method for asymmetric epoxidation
US4594439A (en) * 1980-08-06 1986-06-10 The Board Of Trustees Of The Leland Stanford Jr. University Method for asymmetric epoxidation
US4900847A (en) * 1985-04-04 1990-02-13 Massachusetts Institute Of Technology Catalytic asymmetric epoxidation
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
WO1998009964A1 (en) 1996-09-03 1998-03-12 Bristol-Myers Squibb Company IMPROVED PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE
EE05442B1 (et) * 2000-02-29 2011-08-15 Bristol-Myers Squibb Company V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks
TWI275392B (en) 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
CN101899063B (zh) * 2002-12-11 2012-12-12 布里斯托尔-迈尔斯斯奎布公司 制备抗病毒药[1S-(1α,3α,4β)]-2-氨基-1,9-二氢-9-[4-羟基-3-(羟甲基)-2-亚甲环戊基]-6H-嘌呤-6-酮的方法

Also Published As

Publication number Publication date
CA2569484A1 (en) 2005-12-15
EP1751158A1 (en) 2007-02-14
US7968555B2 (en) 2011-06-28
JP2008501711A (ja) 2008-01-24
IL179753A0 (en) 2007-05-15
JP5236288B2 (ja) 2013-07-17
US20100286089A1 (en) 2010-11-11
AU2005251377A1 (en) 2005-12-15
EP1751158A4 (en) 2009-05-13
US20090143578A1 (en) 2009-06-04
RU2006146967A (ru) 2008-07-20
MXPA06014003A (es) 2007-02-08
RU2384582C2 (ru) 2010-03-20
WO2005118585A1 (en) 2005-12-15
US7786300B2 (en) 2010-08-31
KR20070029737A (ko) 2007-03-14
NO20066078L (no) 2007-02-01
US20050272932A1 (en) 2005-12-08
US7511139B2 (en) 2009-03-31

Similar Documents

Publication Publication Date Title
HUP0302345A2 (hu) Új triazolo-pirimidin-vegyületek, ezek intermedierjei és eljárás az előállításukra
AR050254A1 (es) Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas
BRPI0507877A (pt) derivados de formamida, composição farmacêutica, uso dos mesmos e combinação
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
BRPI0913457A2 (pt) "composto, composição farmacêutica, e, uso do composto"
NO20084005L (no) Aminderivater
CA2495967A1 (fr) Nouveau procede de synthese et nouvelle forme cristalline de l'agomelatine ainsi que les compositions pharmaceutiques qui la contiennent
ATE513833T1 (de) Thienopyridinverbindungen und verfahren zu ihrer verwendung
BRPI0712631A8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BRPI0414799A (pt) bifenilóxi-ácidos
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
CL2011003144A1 (es) Forma cristalina e3 de bisulfato de atazanavir; composicion farmaceutica que la comprende; util para el tratamiento de enfermedades originadas por retrovirus (divisional de la solicitud 1057-05).
ITMI20020281A1 (it) Composti fosfazenici ciclici e loro uso come addittivi di oli perfluoropolieterei
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
CR9182A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
BRPI0519710A2 (pt) aminoÁlcoois tricÍclicos, processo para sua preparaÇço e seu emprego como anti-inflamatàrio
ATE517900T1 (de) Heptarylen-und octarylentetracarbonsäurediimide und deren herstellung
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
BRPI0414678A (pt) forma polimórfica de 3-fenil sulfonil-8-piperazin-1-il quinolina
BRPI0409154A (pt) processo para a preparação de 5-(haloacetil)-8-(óxi substituìdo)-(1h)-quinolin-2-onas
BRPI0508927A (pt) compostos úteis para o tratamento de doenças

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND (CH)

B25G Requested change of headquarter approved

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND (CH)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2468 DE 24/04/2018 POR TER SIDO INDEVIDA.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]